Alnylam Non Current Assets Total from 2010 to 2024

ALNY Stock  USD 149.96  6.01  4.18%   
Alnylam Pharmaceuticals Non Current Assets Total yearly trend continues to be fairly stable with very little volatility. Non Current Assets Total are likely to outpace its year average in 2024. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
2003-12-31
Previous Quarter
847.2 M
Current Value
835.8 M
Quarterly Volatility
363.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 M, Interest Expense of 127.3 M or Other Operating Expenses of 2.2 B, as well as many exotic indicators such as Price To Sales Ratio of 12.42, Dividend Yield of 0.0 or Days Sales Outstanding of 60.78. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Alnylam Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Alnylam Pharmaceuticals Technical models . Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of Alnylam Pharmaceuticals over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Alnylam Pharmaceuticals' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

Alnylam Non Current Assets Total Regression Statistics

Arithmetic Mean422,832,877
Geometric Mean149,812,394
Coefficient Of Variation98.20
Mean Deviation364,907,185
Median273,569,000
Standard Deviation415,229,792
Sample Variance172415.8T
Range1.2B
R-Value0.88
Mean Square Error40584.3T
R-Squared0.78
Significance0.000012
Slope82,076,307
Total Sum of Squares2413820.9T

Alnylam Non Current Assets Total History

2024889.5 M
2023847.2 M
2022854.1 M
2021774.5 M
20201.2 B
2019661.2 M
2018365.5 M

About Alnylam Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Alnylam Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Alnylam Pharmaceuticals investors use historical funamental indicators, such as Alnylam Pharmaceuticals's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Alnylam Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Alnylam Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alnylam Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Alnylam Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Assets Total847.2 M889.5 M

Pair Trading with Alnylam Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Alnylam Stock

  0.72MOR MorphoSys AG ADRPairCorr
  0.65LLY Eli Lilly Earnings Call This WeekPairCorr
  0.6INDP Indaptus Therapeutics Earnings Call TodayPairCorr
  0.58GBIO Generation BioCo Financial Report 8th of May 2024 PairCorr
  0.53VTYX Ventyx Biosciences Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alnylam Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alnylam Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alnylam Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alnylam Pharmaceuticals Stock:
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Alnylam Stock analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stocks Directory
Find actively traded stocks across global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.52)
Revenue Per Share
14.637
Quarterly Revenue Growth
0.312
Return On Assets
(0.05)
Return On Equity
(15.01)
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.